Product Description
Since last manyyears SaintroyLifescienceis leading manufacture, export and supplierofIdarubicin Hydrochloride for Injectionfrom Surat, Gujarat, India. Idarubicin Hydrochloride for Injection used for treatment of acute lymphoblastic leukemia and chronic myelogenous leukemia in blast crisis.
Tags: Idarubicin Hydrochloride for Injection manufacturer, Idarubicin Hydrochloridefor Injection exporter, Idarubicin Hydrochloride for Injection supplier,and Idarubicin Hydrochloride for Injection, whogmp approved Idarubicin Hydrochloridefor Injection manufacturer and supplier, Idarubicin Hydrochloride ForInjection distributor, Idarubicin Hydrochloride for Injection shipper, Idarubicin Hydrochloridefor Injection 20 ml Idarubicin Hydrochloride for Injection 20 mlsupplier,Idarubicin Hydrochloride for Injection 20 ml.
ISO/GMP/cGMP/WHOGMP/NAFDAC approved, PPB Kenya approved/USFDA approved/EUGMP approved/MOH Iran approved manufacturingfacility in Gujarat, India.
Registration: Saintroy Lifescienceis interested in registrationof own brand or customer brands in ministryof health of clientscountry and we also provide the products samples, COA, COPP, ACTD or CTD dossier, DMF, Manufacturing license, Free sales certificate and other required documents.
Export Country:Saintroy Lifescience Idarubicin Hydrochloridefor Injection export to USA, Canada, Germany, Europe, France,Ghana, Nigeria, Kenya, Senegal, Sudan,UAE, Kuwait, Dubai, Cameroon, Lebanon,Peru, Chile, Somalia, Philippines, Myanmar, Maldives, Thailand, Singapore,Malaysia, Hong Kong, China, Zimbabwe, Togo, Burkina Faso, Niger,Guinea Bissau,Congo, Democratic of republic, Ivory Costa, Oman, Guatemala, Nicaragua,Salvador, Qatar, Costa Rica, Panama, Cuba, Colombia, Bolivia, Argentine,Algeria, Guyana, Morocco, Jordan, Bahrain, Iran, Egypt, Kyrgyzstan, Uzbekistan,Kazakhstan.
Effective Treatment for AMLIdarubicin Hydrochloride for Injection is a vital therapy in the management of Acute Myeloid Leukemia (AML). Its cytotoxic activity targets rapidly dividing cells, offering significant benefits in remission induction when administered as recommended by clinical protocols. The product is supplied in reliable glass vials, supporting stable dosage and consistent efficacy.
Strict Quality Compliance and SafetyThis medication meets stringent USP/BP pharmacopeial standards, ensuring patients and providers receive a high-quality pharmaceutical product. As a cytotoxic agent, professionals must handle it with caution, adhering to all hospital safety guidelines. The flip-off cap packaging enhances secure access and reduces contamination risk during preparation.
FAQ's of Idarubicin Hydrochloride for Injection:
Q: How is Idarubicin Hydrochloride for Injection prepared and administered?
A: The powder must be reconstituted with sterile water for injection, yielding a solution with a pH of 4.0-5.0. It is then administered intravenously by healthcare professionals only, not for self-administration.
Q: What is the primary indication for using Idarubicin Hydrochloride for Injection?
A: This medication is indicated for the treatment of Acute Myeloid Leukemia (AML), providing an effective cytotoxic option as part of a hospital-administered chemotherapy protocol.
Q: When should Idarubicin Hydrochloride for Injection be used?
A: Idarubicin should only be employed under medical supervision, typically within the structured schedules of oncology treatment centers based on a physician's guidance.
Q: Where should this medication be stored and prepared?
A: Store this product in a cool, dry location as directed. Reconstitution and preparation must occur in a hospital or approved clinical setting with appropriate cytotoxic handling protocols.
Q: What are the safety precautions for handling Idarubicin Hydrochloride?
A: Handle as a cytotoxic agent, wearing protective equipment and ensuring all preparation occurs in designated hospital areas to minimize exposure and environmental risk.
Q: What benefits does Idarubicin Hydrochloride offer in cancer treatment?
A: Idarubicin Hydrochloride provides targeted action against malignant cells in AML, contributing to remission rates and improving patient outcomes under strict medical supervision.